Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

DUPIXENT REDUCED STEROID USE AND
SURGERY FOR THE MAJORITY OF PATIENTS

Significantly reduced SCS use or the need for sino-nasal surgery vs placebo in a prespecified multiplicity-controlled pooled analysis of Trials 1 and 21,a

Time to first scs use or CRSwNP surgery
during the treatment period
76%
Reduction

at Week 52
with DUPIXENT vs placebo (HR: 0.24 [95% CI: 0.17, 0.35])

  • DUPIXENT 300 mg
    Q2W + INCS

    (Day 0: n=438; Week 24: n=376; Week 52: n=100)
  • Placebo + INCS
    (Day 0: n=286; Week 24: n=187; Week 52: n=61)
74%
Fewer patients
required scs use
at week 52
(HR: 0.26 [95% CI: 0.18, 0.38])1
  • 75% Reduction In SCS COURSES PER YEAR
    (RR: 0.25 [95% CI: 0.17, 0.37])1
83%
Fewer patients required Sino-nasal surgery at week 52
(HR: 0.17 [95% CI: 0.07, 0.46])1
  • aIndividually, SCS reduction and need for sino-nasal surgery were not multiplicity-adjusted endpoints.
  • CRSwNP, chronic rhinosinusitis with nasal polyposis; HR, hazard ratio; INCS, intranasal corticosteroids; Q2W, once every 2 weeks; RR, risk ratio; SCS, systemic corticosteroid.

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

Reference:

  1. DUPIXENT Prescribing Information.